Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04113993
PHASE4

Bazedoxifene -Treatment for Women With Schizophrenia

Sponsor: The Alfred

View on ClinicalTrials.gov

Summary

To study the effect of adjunctive bazedoxifene - a selective estrogen receptor modulator (SERM) in a double blind, placebo-controlled adjunctive study in the treatment of women with schizophrenia. All patients receive standardized antipsychotic medication.

Official title: Bazedoxifene - A New Selective Estrogen Receptor Modulator Treatment for Women With Schizophrenia: a Double-blind, Randomized, Placebo Controlled Trial

Key Details

Gender

FEMALE

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

160

Start Date

2019-10-07

Completion Date

2026-12-31

Last Updated

2026-06-03

Healthy Volunteers

No

Interventions

DRUG

Bazedoxifene Acetate

Oral Bazedoxifene dosed at 40 mg daily for 12 weeks

DRUG

Placebo

Identically packaged placebo capsule daily

Locations (1)

Multidisciplinary Alfred Psychiatry Research Centre

Melbourne, Victoria, Australia